The impact of body weight on rivaroxaban pharmacokinetics-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The impact of body weight on rivaroxaban pharmacokinetics

Published:2017-10 Issue:2 Volume:1 Page:180-187
ISSN:2475-0379
Container-title:Research and Practice in Thrombosis and Haemostasis
language:en
Short-container-title:Res Pract Thromb Haemost

Author:

Barsam Sarah J.¹,Patel Jignesh P.¹²^ORCID,Roberts Lara N.¹,Kavarthapu Venu³,Patel Raj K.¹,Green Bruce⁴,Arya Roopen¹

Affiliation:

1. Department of Haematological Medicine; King's Thrombosis Centre; King's College Hospital Foundation NHS Trust; London UK

2. Institute of Pharmaceutical Science; King's College London; London UK

3. Department of Orthopaedic Surgery; King's College Hospital Foundation NHS Trust; London UK

4. Model Answers Pty Ltd; Brisbane Qld Australia

Publisher

Wiley

Subject

Hematology

Reference32 articles.

1. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis;Sterne;Health Technol Assess,2017

2. Rates, management and outcome of bleeding complications during rivaroxaban therapy in daily care: results from the Dresden NOAC registry;Beyer-Westendorf;Blood,2014

3. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study;Ageno;Lancet Haematol,2016

4. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation;Camm;Eur Heart J,2016

5. New anticoagulants: dosing and monitoring;Patel;BMJ,2015

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Establishing a risk prediction model for residual pulmonary vascular obstruction after regular anticoagulant therapy for non-high-risk pulmonary embolism;Journal of Thoracic Disease;2024-07

2. Pharmacokinetics of single‐dose rivaroxaban under fed state in obese vs. non‐obese subjects: An open‐label controlled clinical trial (RIVOBESE‐PK);Clinical and Translational Science;2024-06

3. Impact of Obesity on Atrial Fibrillation Pathogenesis and Treatment Options;Journal of the American Heart Association;2024-01-02

4. Direct Oral Anticoagulants in Special Patient Populations;Journal of Clinical Medicine;2023-12-29

5. Poor Correlation of Rivaroxaban Concentration with the Routine Coagulation Screening Test in Chinese Patients with Atrial Fibrillation;Journal of Clinical Pharmacy and Therapeutics;2023-10-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3